CTMX

News Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit

7d ago

News CytomX (CTMX) Q2 Revenue Drops 26%

14d ago

News CytomX expects cash runway to at least the second half of 2028 as Varseta-M targets a first half of 2027 registrational study

25d ago

Insider trade Sale by Yu-Waye Chu (Chief Medical Officer)

74d ago

Insider trade Sale by Sean A. Mccarthy (CEO)

74d ago

Insider trade Sale by Christopher Ogden (Chief Financial Officer)

74d ago

Insider trade Sale by Marcia Belvin (SVP, Chief Scientific Officer)

74d ago

SEC filing CTMX Prices $5.30 Offering, Sells 45.99M Shares + Warrants, $234.4M Net Proceeds

74d ago

News CytomX outlines registrational trial plans for Varseta-M in third-line colorectal cancer with initial study start in 2027

78d ago

News J.P. Morgan outlines CRM options play for uncertain Iran war outcome

78d ago

News CytomX GAAP EPS of -$0.15 misses by $0.12, revenue of $76.2M misses by $6.69M

78d ago

SEC filing CTMX Reports $76.2M Revenue, $137.1M Cash, Positive Varseta-M CRC Data, FDA Target Mid‑2026, CX‑801 Combination 2026

78d ago

News Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

105d ago

News Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States

146d ago

News AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth

153d ago

News CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

153d ago

Scanner Unusual volume (z=3.8)

160d ago

Scanner Unusual volume (z=3.9)

161d ago

Scanner Unusual volume (z=3.9)

163d ago

Scanner Unusual volume (z=7.2)

164d ago

Scanner Unusual volume (z=2.8)

165d ago